GSK, RSV
GSK reports positive findings from Phase III RSV vaccine trial
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ages of 70 and 79 years.
GSK, Pfizer seeing drop in demand for RSV vaccines: report
RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots. Read more here.
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0
GSK's RSV vac­cine Arexvy shows long-term pro­tec­tion in Phase 3 tri­al
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST 2024 Annual Meeting. In the Phase 3 trial, called AReSVi-006, a dose of Arexvy was 62.
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating
GSK Arexvy protects from RSV over three full seasons
GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a Phase 3 trial. Read more here.
FiercePharma1d
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
kffhealthnews6h
GSK’s Widely Used RSV Shot Retains 43% Potency In Third Year, Data Show
Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...
STAT5d
After a rocky debut for new RSV tools, hopes are high as a new season approaches
Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...
Monthly Prescribing Reference21d
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
The most frequently reported adverse reactions were injection site pain ... pharmacies and ultimately help to get ahead of RSV and shingles.” Arexvy is indicated for active immunization for ...
Seeking Alpha21d
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV ... with the duration of adverse events, such as injection site pain and fatigue, comparable ...
Yahoo Finance1d
RSV can be deadly, especially for older adults. What to know about symptoms and the new vaccine
The Food and Drug Administration (FDA) approved the nation’s first RSV vaccine, GSK’s Arexvy, on May 3, 2023. In a statement that day, Dr. Peter Marks, director of the FDA’s Center for Biologics ...